Abstract: Objective To observe the clinical effects of Liuweiwuling tablets in combination with entecavir (ETV) on chronic hepatitis B patients with HBeAg positive. Methods Total of 102 chronic hepatitis B patients with HBeAg positive were randomly divided into treatment group and control group: the control group were treated with ETV (0.5 mg/d) for 52 weeks; while the treatment group were  treated with Liuweiwuling  tablets, besides the ETV (0.5 mg/d) therapy for 52 weeks. The liver and kidney function, serum HBeAg and HBV DNA were observed at the 12, 24, 52 weeks. Results The ALT recovery rate of treatment group and control group were 88%, 69.23% at 52 weeks respectively, there were significant statistical differences between the two groups (P ＜ 0.01); the seroconversion rate of HBeAg/HBeAb are 34%, 25%, respectively (P ＜ 0.05). Conclusions The liver function index and the seroconversion rate of HBeAg/HBeAb in treatment group are better than control group, Liuweiwuling tablets in combination with ETV has a great cooperative effect on inhibiting hepatitis B virus for chronic hepatitis B patients with HBeAg positive.